Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.
Lagos
Rosanna
R
Centro Para Vacunas En Desarrollo-Chile, Santiago, Chile.
DeVincenzo
John P
JP
Muñoz
Alma
A
Hultquist
Micki
M
Suzich
Joann
J
Connor
Edward M
EM
Losonsky
Genevieve A
GA
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010919:Placebos / Q000008:administration & dosage; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000276:immunology; D012137:Respiratory System / Q000821:virology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D000998:Antiviral Agents; D010919:Placebos; C506968:motavizumab